; The Behavioral Measurement Shared Resource (BMSR) provides expert assistance and services for integrating behavioral research into the research goals of the OSUCCC. Since its inaugural year in 2004, there has been a greater than 12-fold increase in usage: in 2009, nearly 20,000 hours of service was provided and 93.36% of that usage came from funded OSUCCC members. This increase in usage is expected to continue. The BMSR is directed by Dr. Michael Slater with assistance from six senior staff and strong institutional support. Together, they provide leadership and coordination of the Shared Resource to enhance high quality cancer relevant investigations.
The specific aims of the BMSR are to: 1. Support prevention and control researchers by providing population-based data retrieval, consultation for patient accrual procedures and locations, identifying or adapting existing measures of key behavioral constructs and guidance or assistance with behavioral data collection methodology and/or personnel; 2. Provide any OSUCCC investigator with this support as well as research design expertise for the incorporation of behavioral aims within any basic or clinical cancer research project. Specifically, the BMSR supports the following services within peer-reviewed funded research: 1) research design;2) population-based data retrieval;3) recruitment and accrual, particularly with under served and minority populations;4) behavioral assessment;and 5) data collection. The availability of design and behavioral measurement consultations enables investigators to reduce time for project development and speed the research process. To enhance National Cancer Institute and OSUCCC goals to support outstanding population science research projects, the BMSR services ensure the inclusion of: research participants that are broadly representative of the target population(s);behavioral constructs that are theoretically and empirically supported;behavioral measures that are psychometrically sound;standardized assessment procedures for reliable data collection and management and expertise for consultation regarding analysis of behavioral data. Thus, the BMSR provides a continuum of services, ranging from planning for and developing research proposals and projects, through data collection and the interpretation of behavioral data. OSUCCC members with peer-reviewed funding account for 93.36 % of the total usage and is derived from five of the six OSUCCC scientific programs including Cancer Control (CC), Innate Immunity (IMM), Molecular Biology and Cancer Genetics (MBCG) and Molecular Carcinogenesis and Chemoprevention (MCC).
; BMSR provides OSUCCC investigators with capability to develop proposals and execute high-quality, sophisticated behavioral research. Services range from intensive recruitment and data collection in hard-to reach populations that may involve thousands of participants, to providing young investigators and clinical researchers with occasional behavior research needs through assistance with design, measurement, recruitment and data collection at a level of expertise that would otherwise be unavailable to them.
|Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572|
|Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5|
|Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73|
|Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75|
|Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174|
|Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643|
|Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723|
|Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365|
|Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086|
|Pagotto, Sara; Veronese, Angelo; Soranno, Alessandra et al. (2018) Hsa-miR-155-5p drives aneuploidy at early stages of cellular transformation. Oncotarget 9:13036-13047|
Showing the most recent 10 out of 2602 publications